| Market Cap | 11.99M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -31.01M | Forward P/E | -0.74 | EPS next Y | - | 50D Avg Chg | -36.00% |
| Sales | 661.98k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -64.00% |
| Dividend | N/A | Price/Book | 0.26 | EPS next 5Y | - | 52W High Chg | -87.00% |
| Recommedations | 1.70 | Quick Ratio | 3.50 | Shares Outstanding | 13.25M | 52W Low Chg | 1.00% |
| Insider Own | 55.91% | ROA | -35.13% | Shares Float | 1.35B | Beta | -0.12 |
| Inst Own | 27.05% | ROE | -80.80% | Shares Shorted/Prior | 120.38K/333.37K | Price | 1.47 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 9,882 | Target Price | 6.00 |
| Oper. Margin | -9,466.24% | Earnings Date | Sep 30 | Volume | 29,203 | Change | -13.02% |
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.